AlphAIAlphAI — Financial news for AI agents
StockOTC · US · USDHealthcare · Drug Manufacturers - Specialty & Generic

$ELTP

ELITE PHARMACEUTICALS INC /NV/

Price · $ELTPvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ELTP in the last 7 days.

Insider · 30dAll trades →
Buys
$26K
1 txs
Sells
—
0 txs
Dash Barry H1× · $26K
10b5-1 share of filings0%
See all $ELTP insider activity →
Top stories · $ELTPMore →
AUG 18·yahoo.com

Elite Pharmaceuticals Inc (ELTP) (Q1 2027) Earnings Call Highlights: Steady Revenue

Elite Pharmaceuticals (ELTP) Q1 FY2027 earnings call said revenue and operating profit were lower year over year due to normalization after the initial Vyvanse generic launch. CFO cited rising volumes and a non-cash working capital drop from warrant reclassification. CEO discussed proposed generic drug tariffs, Nasdaq uplisting by about Feb 2027, and FDA issues affecting an Oxy ER launch timeline.

ELTP sentiment & insider activity

Recent ELTP coverage spans earnings and insider activity.

In the last 30 days, ELTP insiders filed 1 SEC Form 4 transaction — 1 purchase ($26K) and no sales. The most active reporter was Dash Barry H with 1 filing.

What's driving ELTP

  • Small insider buy may signal confidence but size is modest.

    SEC EDGAR · Oct 19, 2026

  • Small insider purchase signals confidence but limited market impact.

    SEC EDGAR · Sep 10, 2026

  • Near-term trading hinges on (1) continued volume growth despite price normalization, (2) Nasdaq uplisting execution by early 2027, and (3) FDA in-vitro anti-abuse smokability testing potentially delaying the August 2027 Oxy ER launch.

    yahoo.com · Aug 18, 2026

  • This 8-K is a filing-and-disclosure update tied to the company’s quarterly results, but the excerpt provides no new financial figures or guidance.

    SEC EDGAR 8-K · Aug 13, 2026

  • This is a filing-and-call catalyst rather than a quantified earnings surprise in the scraped text.

    SEC EDGAR 8-K · Jun 29, 2026

AlphAI scores every news story that mentions ELTP with an AI model for sentiment and relevance, and aggregates insider trades from ELITE PHARMACEUTICALS INC /NV/'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ELTP

Score
AUG 18$ELTPMedyahoo.com

Elite Pharmaceuticals Inc (ELTP) (Q1 2027) Earnings Call Highlights: Steady Revenue

Elite Pharmaceuticals (ELTP) Q1 FY2027 earnings call said revenue and operating profit were lower year over year due to normalization after the initial Vyvanse generic launch. CFO cited rising volumes and a non-cash working capital drop from warrant reclassification. CEO discussed proposed generic drug tariffs, Nasdaq uplisting by about Feb 2027, and FDA issues affecting an Oxy ER launch timeline.

4 min read
AUG 13$ELTPLowSEC EDGAR 8-K

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026

ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, NJ – August 13, 2026: Elite P

2 min read
JUN 29$ELTPLowSEC EDGAR 8-K

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026

ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001053369 0001053369 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2026

2 min read

Related tickers

More in Drug Manufacturers - Specialty & Generic